<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337581</url>
  </required_header>
  <id_info>
    <org_study_id>No.2017-62</org_study_id>
    <nct_id>NCT03337581</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics and Pharmacokinetics of Dexmedetomidine in Pediatric</brief_title>
  <official_title>The Safety、Efficacy and Pharmacokinetics of Dexmedetomidine Administered Through Different Routes in Pediatric</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Medical Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Medical Association</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Acute Hemodynamic and respiratory Changes After Rapid Intravenous different doses of
           Dexmedetomidine in Pediatric.

        2. Pharmacokinetics after a single Rapid Intravenous dose of Dexmedetomidine in Pediatric.

        3. Pharmacokinetics after a single dose of Dexmedetomidine administered as a nasal spray in
           Pediatric.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Hemodynamic and respiratory Changes After Rapid Intravenous of Dexmedetomidine</measure>
    <time_frame>up to 4 months</time_frame>
    <description>Acute Hemodynamic and respiratory Changes After Rapid Intravenous different doses of Dexmedetomidine in Pediatric</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics after a single Rapid Intravenous dose of Dexmedetomidine in Pediatric</measure>
    <time_frame>up to 6 months</time_frame>
    <description>After a single Rapid Intravenous dose of Dexmedetomidine in Pediatric，blood samples will be collected ,and dexmedetomidine plasma concentrations were measured with High Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Dexmedetomidine administered as a nasal spray</measure>
    <time_frame>up to 6 months</time_frame>
    <description>After a single dose of Dexmedetomidine administered as a nasal spray in Pediatric,blood samples will be collected ,and dexmedetomidine plasma concentrations were measured with High Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS).</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">187</enrollment>
  <condition>Pediatrics</condition>
  <condition>Dexmedetomidine</condition>
  <condition>Pharmacodynamics</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>group 1.1</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Normal saline group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 1.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25μg/kg dexmedetomidine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 1.3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5μg/kg dexmedetomidine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 1.4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.75μg/kg dexmedetomidine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 1.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0μg/kg dexmedetomidine group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>see arms</description>
    <arm_group_label>group 1.1</arm_group_label>
    <arm_group_label>group 1.2</arm_group_label>
    <arm_group_label>group 1.3</arm_group_label>
    <arm_group_label>group 1.4</arm_group_label>
    <arm_group_label>group 1.5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  selective operation of inguinal hernia repair、orthopedics operation or general surgery
             operation in children

          -  aged 3-9 years

          -  ASA I - II

          -  enter the operating room by himself without parents

          -  normal liver and kidney function

          -  no history of anesthesia medication allergy.

        Exclusion Criteria:

          -  allergic to dexmedetomidine, similar active ingredients or excipients

          -  G-6-PD deficiency

          -  a history of arrhythmia, bronchial and cardiovascular diseases, abnormal liver
             function and so on

          -  a history of use of alpha 2 receptor agonists or antagonists.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huacheng Liu</last_name>
    <role>Study Director</role>
    <affiliation>The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang Chen</last_name>
    <phone>+86 13957776300</phone>
    <email>15254896@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chengyu Wang</last_name>
    <phone>+8615158719196</phone>
    <email>15158719196@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Chen</last_name>
      <phone>0577-88002560</phone>
      <email>feykjkcy@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xueqiong Zhu</last_name>
      <phone>0577-88002560</phone>
      <email>feykjkcy@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chengyu Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>pediatrics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

